专与D-二元比率:在高级肺腺癌患者中评估一线化疗疗效果的新预后因素
Liqun Zhang1,2, Xing Li3, Zhuo Wang4
1School of Biomedical Engineering, Faculty of Medicine, Dalian University of Technology, Ganjingzi District, Dalian, Liaoning, China.
Neoplasma
|March 20, 2024
概括
专与D-二聚合物比率 (ADR) 是晚期肺腺癌 (LUAD) 的新预后指标. 在接受一线化疗的患者中,高ADR预测了更好的结果和更长的无进展生存期 (PFS).
科学领域:
- 在瘤学瘤学.
- 生物标志物 生物标志物
- 临床化学 临床化学
背景情况:
- 晚期肺腺癌 (LUAD) 的预后不好,主要治疗方法是化疗.
- 预测LUAD治疗疗效对于患者管理至关重要.
- 白蛋白和D-二次体是已知的预后标记物,但它们在LUAD中的综合比率 (ADR) 尚未被探索.
研究的目的:
- 在先进的LUAD患者中,研究治疗前的白蛋白与D-二分体比率 (ADR) 的预后价值.
- 评估ADR与临床病理特征和化疗反应的关联.
- 确定ADR是否可以预测晚期LUAD中无进展生存 (PFS).
主要方法:
- 对313名先进的LUAD患者进行了回顾性分析,这些患者接受了一线基化疗.
- 接收器操作特征 (ROC) 分析以确定ADR值.
- 考克斯回归和卡普兰-梅尔分析,以评估预后因素和生存率.
主要成果:
- ADR显示出优越的预测能力超过了白蛋白,D-二元和白蛋白与纤维素因子比率 (AFR).
- 高ADR (≥16.608) 与非吸烟状态,较高的BMI和较高的Na+水平有关.
- 高ADR与改善的疾病控制率 (DCR),整体反应率 (ORR) 和显著更长的PFS相关.
结论:
- 专与D模比 (ADR) 是一种新的,独立的预后生物标志物,用于高级的LUAD.
- 在预测化疗反应和PFS方面,ADR优于个体标志物和AFR.
- ADR可以帮助评估治疗效果,并指导高级LUAD患者的临床决策.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...